N-Lorem and EspeRare Collaborate to Enhance Access to ASO Therapies in Europe

n-Lorem Foundation and EspeRare Foundation have announced a partnership to broaden access in Europe to n-Lorem's antisense oligonucleotide (ASO) therapies for rare genetic diseases. Initially targeting a few patients in Switzerland, the collaboration seeks to overcome regulatory and operational challenges outside the U.S., aiming for wider European access.

The initiative will leverage EspeRare's expertise in regulatory navigation and network building to develop frameworks that ensure patient safety and scientific integrity. The collaboration will focus on enabling ASO therapies for nano-rare patients, a unique group with very few treatment options. Both organizations aim to establish scalable access models across Europe, supported by a joint steering committee.